Back to top
more

Intercept Pharmaceuticals, Inc. (ICPT)

(Delayed Data from NSDQ)

$89.92 USD

89.92
705,568

+1.71 (1.94%)

Updated May 3, 2019 04:00 PM ET

After-Market: $89.98 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What to Expect from Keryx (KERX) this Earnings Season?

by Zacks Equity Research

Keryx Biopharmaceuticals, Inc. (KERX) intends to focus on the growth of Auryxia in the U.S. dialysis market. The company is also making efforts for label expansion on Auryxia in the iron-deficiency anemia (IDA) indication.

    Is a Beat in Store for Alexion (ALXN) this Earnings Season?

    by Zacks Equity Research

    Alexion Pharmaceuticals, Inc.'s (ALXN) drugs like Soliris and Strensiq have been performing well. Let's see if these lead the company to an earnings beat.

      Intercept (ICPT) Releases Data from Phase II Flint Trial

      by Zacks Equity Research

      Intercept Pharmaceuticals, Inc. (ICPT) announced a retrospective analysis of the phase II trial, FLINT, in patients who were diagnosed with nonalcoholic steatohepatitis (NASH) and type II diabetes.

        Intercept (ICPT) Down 3.5% Since Earnings Report: Can It Rebound?

        by Zacks Equity Research

        Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

          Intercept Pharmaceuticals (ICPT) Looks Good: Stock Adds 5.3% in Session

          by Zacks Equity Research

          Intercept Pharmaceuticals, Inc. (ICPT) was a big mover last session, as the company saw its shares rise over 5% on the day with a solid volume as well.

            Intercept's (ICPT) Liver Drug Ocaliva Approved in Canada

            by Zacks Equity Research

            Intercept Pharmaceuticals, Inc. (ICPT) announced that livver drug Ocaliva has obtained approval in Canada also.

              Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat

              by Zacks Equity Research

              Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.61 per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of $4.27.

                Ekta Bagri headshot

                Intercept (ICPT) Reports A Narrower Loss in Q1

                by Ekta Bagri

                Intercept Pharma posted a loss of $4.27, while the company reported a loss of $3.61 in the first quarter of 2017.

                  Radius Health (RDUS) Q1 Earnings: What's in Store?

                  by Zacks Equity Research

                  Radius Health, Inc. (RDUS) is scheduled to report first-quarter 2017 financial results on May 3.

                    Is Intercept (ICPT) Poised for a Beat This Earnings Season?

                    by Zacks Equity Research

                    Is Intercept (ICPT) Poised for a Beat this Earnings Season?

                      Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?

                      by Zacks Equity Research

                      Gilead Sciences Inc. (GILD) is scheduled to report first-quarter 2017 results on May 2, after the market closes.

                        Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?

                        by Zacks Equity Research

                        Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.

                          Celgene (CELG) to Post Q1 Earnings: What's in the Cards?

                          by Zacks Equity Research

                          Celgene Corporation (CELG) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.

                            Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again?

                            by Zacks Equity Research

                            We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports first-quarter 2017 results on Apr 26 after the market closes.

                              Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise?

                              by Zacks Equity Research

                              Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report first quarter 2017 results on Apr 27, before the opening bell.

                                Novartis (NVS) Q1 Earnings: Will the Stock Disappoint?

                                by Zacks Equity Research

                                Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report first-quarter 2017 results on Apr 25.

                                  Allergan (AGN) Collaborates with Novartis to Treat NASH

                                  by Zacks Equity Research

                                  Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis

                                    Intercept (ICPT) Q4 Loss Wider than Expected, Revenues Beat

                                    by Zacks Equity Research

                                    Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $4.84 per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of a loss of $3.58.

                                      Ekta Bagri headshot

                                      Intercept (ICPT) Reports a Wider Q4 Loss

                                      by Ekta Bagri

                                      Intercept (ICPT) posted a wider loss in the fourth quarter although revenues beast estimates.

                                        Intercept (ICPT) to Post Q4 Earnings: What's in the Cards?

                                        by Zacks Equity Research

                                        Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report fourth-quarter 2016 results on Feb 23.

                                          Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug

                                          by Zacks Equity Research

                                          Shares of Alcobra Ltd. (ADHD) declined 50.7% after the company reported disappointing top-line results from a phase III study, MEASURE, on ADHD drug, metadoxine, extended release.

                                            Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?

                                            by Zacks Equity Research

                                            Shares of Merrimack Pharmaceuticals Inc (MACK) have increased 47.9% in the last twelve months as the company looks to restructure business.

                                              Intercept Pharmaceuticals (ICPT) Jumps: Stock Rises 9.3%

                                              by Zacks Equity Research

                                              Intercept Pharmaceuticals, Inc. (ICPT) shares rose over 9% in the last trading session.

                                                Intercept (ICPT) Ocaliva Gains Conditional Approval in EU

                                                by Zacks Equity Research

                                                Intercept (ICPT) Ocaliva, in combination with UDCA, was approved in the EU for the treatment of PBC.

                                                  Brian Bolan headshot

                                                  Biotech Stocks To Watch

                                                  by Brian Bolan

                                                  The sector has several names on the move today, be sure to check out why with this informative article.